Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy

被引:36
作者
Schönknecht, P
Pantel, J
Hartmann, T
Werle, E
Volkmann, M
Essig, M
Amann, M
Zanabili, N
Bardenheuer, H
Hunt, A
Schröder, J
机构
[1] Univ Heidelberg, Dept Psychiat, Sect Geriatr Psychiat, D-69115 Heidelberg, Germany
[2] Univ Heidelberg, Ctr Mol Biol Heidelberg, ZMBH, D-69115 Heidelberg, Germany
[3] Univ Heidelberg, Dept Internal Med, D-69115 Heidelberg, Germany
[4] German Canc Res Ctr, DKFZ, D-6900 Heidelberg, Germany
[5] Univ Heidelberg, Dept Expt Anesthesia, Heidelberg, Germany
关键词
dementia; differential diagnosis; CSF tau; volumetric MRI;
D O I
10.1016/S0165-1781(03)00197-5
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Increased tau levels are a well-established finding in Alzheimer's disease (AD). In contrast, the potential value of tau levels in the differential diagnosis of AD, vascular dementia (VD) and major depression warrants further investigation. The potential impact of psychotropic medication also needs to be established. We investigated cerebrospinal fluid (CSF) tau protein concentrations in 88 patients with AD, 23 patients with VD, 25 patients with major depression and 17 age-paralleled controls without cognitive impairment with respect to important clinical variables. type and dosage of psychotropic medication and cerebral changes as assessed by magnetic resonance imaging (MRI). The AD patients showed significantly elevated tau levels compared with patients with VD or major depression and controls. Tau levels obtained in the VD group were intermediate, with significant differences from both AD patients and patients with major depression and controls. Within the AD group, no significant correlation between tau levels, severity of dementia, age, duration of disease, type and dosage of psychotropic medication or MRI volumetric changes arose. A subgroup of AD patients without increased tau levels was characterized by a significantly larger percentage of patients with presenile onset. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:231 / 238
页数:8
相关论文
共 40 条
[1]   Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].
Andreasen, N ;
Vanmechelen, E ;
Van de Voorde, A ;
Davidsson, P ;
Hesse, C ;
Tarvonen, S ;
Räihä, I ;
Sourander, L ;
Winblad, B ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305
[2]   Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample [J].
Andreasen, N ;
Minthon, L ;
Clarberg, A ;
Davidsson, P ;
Gottfries, J ;
Vanmechelen, E ;
Vanderstichele, H ;
Winblad, B ;
Blennow, K .
NEUROLOGY, 1999, 53 (07) :1488-1494
[3]   No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia [J].
Arai, H ;
Satoh-Nakagawa, T ;
Higuchi, M ;
Morikawa, Y ;
Miura, M ;
Kawakami, H ;
Seki, H ;
Takase, S ;
Sasaki, H .
NEUROSCIENCE LETTERS, 1998, 256 (03) :174-176
[4]   TAU IN CEREBROSPINAL-FLUID - A POTENTIAL DIAGNOSTIC MARKER IN ALZHEIMERS-DISEASE [J].
ARAI, H ;
TERAJIMA, M ;
MIURA, L ;
HIGUCHI, S ;
MURAMATSU, T ;
MACHIDA, N ;
SEIKI, H ;
TAKASE, S ;
CLARK, CM ;
LEE, VMY ;
TROJANOWSKI, JQ ;
SASAKI, H .
ANNALS OF NEUROLOGY, 1995, 38 (04) :649-652
[5]  
Association A.P., 1987, Diagnostic and Statistical Manual of Mental Disorders-Revision
[6]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[7]  
Buch K, 1998, NERVENARZT, V69, P379, DOI 10.1007/s001150050286
[8]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[9]   High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].
Galasko, D ;
Chang, L ;
Motter, R ;
Clark, CM ;
Kaye, J ;
Knopman, D ;
Thomas, R ;
Kholodenko, D ;
Schenk, D ;
Lieberburg, I ;
Miller, B ;
Green, R ;
Basherad, R ;
Kertiles, L ;
Boss, MA ;
Seubert, P .
ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945
[10]   Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease [J].
Golombowski, S ;
MullerSpahn, F ;
Romig, H ;
Mendla, K ;
Hock, C .
NEUROSCIENCE LETTERS, 1997, 225 (03) :213-215